Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it will collaborate with Perrigo Company with respect to the development and commercialization of two extended topical drug products. The products and terms of the agreement were not disclosed.
“We are excited to collaborate with Perrigo on two extended topical products as we continue to execute our strategy of diversifying our product base. Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms.”
Chris Mengler, president of Global Pharmaceuticals, said: "We are excited to collaborate with Perrigo on two extended topical products as we continue to execute our strategy of diversifying our product base. Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms."